- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
AMA Will Issue New CPT Code for AI Prostate Cancer Mapping Tool
The Current Procedural Terminology (CPT) Category III code for the Unfold AI prostate cancer mapping platform can be utilized by radiologists starting in July 2024.
The 2024 Current Procedural Terminology (CPT) codes from the American Medical Association (AMA) will include a new category III CPT code for the use of Unfold AI, an artificial intelligence (AI)-enabled mapping platform for prostate cancer imaging.
Unfold AI is reportedly the first AI-powered prostate cancer modality to receive a category III CPT code, according to Avenda Health, the manufacturer of Unfold AI.1
Avenda Health said the X237T CPT code, which goes into effect in July 2024, can be utilized for “Non-invasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report.”
"The new CPT code solidifies our position as a frontrunner in revolutionizing cancer care and our commitment to making our technology accessible to all patients,” noted Brittany Berry-Pusey, Ph.D., the COO and co-founder of Avenda Health.
In a retrospective study published earlier this year, researchers found that AI model margins with Unfold AI demonstrated a 96.9 percent sensitivity for diagnosing clinically significant prostate cancer (csPCa) in comparison to 37.4 percent for regions of interest (ROI) on conventional magnetic resonance imaging (MRI).2
References
1. Avenda Health. Avenda Health’s revolutionary AI mapping tool for prostate cancer achieves landmark category III CPT code designation. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/avenda-healths-revolutionary-ai-mapping-tool-for-prostate-cancer-achieves-landmark-category-iii-cpt-code-designation-301973699.html . Published November 1, 2023. Accessed November 1, 2023.
2. Hall J. Study says AI mapping more effective than MRI for assessing extent of prostate cancer. Diagnostic Imaging. Available at: https://www.diagnosticimaging.com/view/study-says-ai-mapping-more-effective-than-mri-for-assessing-extent-of-prostate-cancer . Published June 15, 2023. Accessed November 1, 2023.
What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC
November 13th 2024Researchers found that new prostate lesion detection on SPECT/CT at the beginning of a second cycle of 177 Lu-PSMA-617 for mCRPC was associated with an over sevenfold higher mortality risk.
AI Segmentation, Intraprostatic Tumor Volume and Metastases: What a New mpMRI Study Reveals
October 29th 2024For patients who received radiotherapy for localized prostate cancer, total intraprostatic tumor volume derived from AI segmentation had a 10 percent higher AUC for predicting seven-year metastases in comparison to a risk model from the National Comprehensive Cancer Network (NCCN).
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
